收费全文 | 507805篇 |
免费 | 41699篇 |
国内免费 | 19131篇 |
耳鼻咽喉 | 3378篇 |
儿科学 | 9903篇 |
妇产科学 | 6204篇 |
基础医学 | 85008篇 |
口腔科学 | 8465篇 |
临床医学 | 36080篇 |
内科学 | 90476篇 |
皮肤病学 | 8241篇 |
神经病学 | 37747篇 |
特种医学 | 10196篇 |
外国民族医学 | 119篇 |
外科学 | 36382篇 |
综合类 | 66653篇 |
现状与发展 | 73篇 |
一般理论 | 7篇 |
预防医学 | 28400篇 |
眼科学 | 5681篇 |
药学 | 71173篇 |
91篇 | |
中国医学 | 20435篇 |
肿瘤学 | 43923篇 |
2024年 | 1175篇 |
2023年 | 7769篇 |
2022年 | 16523篇 |
2021年 | 20848篇 |
2020年 | 17001篇 |
2019年 | 17865篇 |
2018年 | 17034篇 |
2017年 | 16747篇 |
2016年 | 16692篇 |
2015年 | 19416篇 |
2014年 | 29031篇 |
2013年 | 32803篇 |
2012年 | 29211篇 |
2011年 | 33862篇 |
2010年 | 28547篇 |
2009年 | 27907篇 |
2008年 | 26927篇 |
2007年 | 25006篇 |
2006年 | 22636篇 |
2005年 | 19337篇 |
2004年 | 16781篇 |
2003年 | 14691篇 |
2002年 | 11692篇 |
2001年 | 10069篇 |
2000年 | 8545篇 |
1999年 | 7661篇 |
1998年 | 6741篇 |
1997年 | 6107篇 |
1996年 | 5438篇 |
1995年 | 4866篇 |
1994年 | 4325篇 |
1993年 | 3689篇 |
1992年 | 3204篇 |
1991年 | 2900篇 |
1990年 | 2505篇 |
1989年 | 2132篇 |
1988年 | 1927篇 |
1987年 | 1618篇 |
1986年 | 1533篇 |
1985年 | 3299篇 |
1984年 | 3818篇 |
1983年 | 2788篇 |
1982年 | 2985篇 |
1981年 | 2629篇 |
1980年 | 2135篇 |
1979年 | 1871篇 |
1978年 | 1432篇 |
1977年 | 1131篇 |
1976年 | 1162篇 |
1975年 | 903篇 |
Area covered: This review presents the management of irAEs resulting from checkpoint blockade, with a focus on rare irAEs.
Expert commentary: With the development of immuno-oncology and the expanding role of ICI, physicians have learnt to diagnose and treat most of the irAEs that can occur. This review provides an overview of current guidelines, previously published studies and our multidisciplinary team based practices. 相似文献
Area covered: The current review is provided to update recent developments in the clinical application of cyclin/CDK inhibitors to breast cancer with a focus on the anti-tumor immune response.
Expert opinion: The cyclin D1 gene encodes the regulatory subunit of a proline-directed serine-threonine kinase that phosphorylates several substrates. CDKs possess phosphorylation site selectivity, with the phosphate-acceptor residue preceding a proline. Several important proteins are substrates including all three retinoblastoma proteins, NRF1, GCN5, and FOXM1. Over 280 cyclin D3/CDK6 substrates have b\een identified. Given the diversity of substrates for cyclin/CDKs, and the altered thresholds for substrate phosphorylation that occurs during the cell cycle, it is exciting that small molecular inhibitors targeting cyclin D/CDK activity have encouraging results in specific tumors. 相似文献
Research design and methods: This multicenter, open-label, single-group, prospective interventional study evaluated changes in total gait-related scores of the Part II/III Movement Disorder Society-Unified Parkinson’s Disease Rating Scale (MDS-UPDRS) and Freezing of Gait Questionnaire (FOG-Q) in 31 Parkinson’s disease patients treated with istradefylline. Gait analysis by portable gait rhythmogram was performed.
Results: MDS-UPDRS Part III gait-related total scores significantly decreased at Weeks 4–12 from baseline with significant improvements in gait, freezing of gait, and postural stability. Significant decreases in MDS-UPDRS Part II total scores and individual item scores at Week 12 indicated improved daily living activities. At Week 12, there were significant improvements in FOG-Q, new FOG-Q, and overall movement per 48 h measured by portable gait rhythmogram. Adverse events occurred in 7/31 patients.
Conclusions: Istradefylline improved gait disorders in Parkinson’s disease patients complicated with freezing of gait, improving their quality of life. No unexpected adverse drug reactions were identified.
Trial registration: UMIN-CTR (UMIN000020288). 相似文献
Areas covered: This review covers the mechanism of action, safety and efficacy of sacituzumab govitecan in patients with previously treated, metastatic TNBC. Additionally, efficacy data in other epithelial malignancies is included based on a PubMed search for ‘sacituzumab govitecan’ and ‘clinical trial’.
Expert opinion: Sacituzumab govitecan has promising anti-cancer activity in patients with metastatic TNBC previously treated with at least two prior lines of systemic therapy based on a single arm Phase I/II clinical trial. A confirmatory Phase III randomized clinical trial is ongoing. Sacituzumab govitecan has a manageable side effect profile, with the most common adverse events being nausea, neutropenia, and diarrhea. The activity of sacituzumab govitecan likely extends beyond TNBC with promising early efficacy data in many other epithelial cancers, including hormone receptor-positive breast cancer. 相似文献